Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN priorities

This article was originally published in The Tan Sheet

Executive Summary

FDA requests comments on CFSAN program priorities for FY 2004, including "new program areas or activities that should be added as high priority" for the year as well as on "which 'B-list' activities should be elevated to the 'A-list' for completion in FY 2004." In 1June 5 Federal Register notice, agency notes it expects "considerable continuity and follow-through between the 2003 and 2004 work plans." For example, FDA notes "new initiatives aimed at increasing the security of our country's food supply...will continue to be a high priority in FY 2004." Comments are due Aug. 4...

You may also be interested in...



CFSAN FY 2004 Priorities Should Start With Bioterror Regs – NFPA

The National Food Processors Association "strongly" recommends that FDA's Center for Food Safety & Applied Nutrition keep implementation of bioterror regs a top priority in fiscal year 2004

The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Topics

UsernamePublicRestriction

Register

PS095542

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel